View this email in your browser
ADVERTISEMENT
Banner Ad 1
FinanceAsia - Finding The Next Opportunity

Tencent joins Zhenkunhang's $160m series D funding
Heading
Chinese industrial products supplier introduces the tech giant as a new investor as it continues its transformation from old-economy company into a fully fledged online distributor.
Biotech IPO candidate

Investors bet on speciality pharmaceuticals in China
Heading
Speciality pharmaceutical company CF PharmTech is looking to raise at least $72 million in funding and has its sights set on an IPO in the near future.
ADVERTISEMENT
Stanford Quantitative Finance Program in HK
Promoted Content

Foreign funds return on resilient fundamentals

By First Metro Investments

The right credit space: Huatai’s structured finance and principal investment business

By Huatai Financial
M&A survey results

Failed M&A deals set to rise as trade war dents sentiment
Heading
Trade tensions and failed deals are preying on the minds of FinanceAsia’s readers as they ponder the M&A landscape for the year ahead.
Editor's Picks
Stock-trading link

Why the London-Shanghai Stock Connect may never take off
Besides Brexit concerns, limited investor demand and the small supply of companies are among the major factors that weigh on the plan to connect London and Shanghai.
Chinese buyouts

Private equity raking over US-China trade war debris for bargains
Disruption caused by the fractious relationship between the world’s two biggest economies spells opportunity for the nimblest investors. Funds are looking to potentially bridge gaps in broken supply chains, take companies private and carve out Chinese units from MNCs.
Secondary listings

Alibaba’s Hong Kong secondary listing plan: it isn’t worth it
The e-commerce giant’s idea of a secondary listing in Hong Kong may not deliver the much-hyped boost in liquidity some bankers are touting; it could also call forth unwanted volatility.
ADVERTISEMENT
Banner Ad 2

For information about this email newsletter,
please contact:
Alison Tudor-Ackroyd
[email protected]

For information about
sponsoring this email newsletter, please contact:
Jonathan Hirst
[email protected]
or
Keith Frith
[email protected]

To unsubscribe: Click Here

© Haymarket Media Ltd.
All Rights Reserved.